ArticleBlood cancer discovery2023

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

Curtis A Lachowiez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.